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Abstract
Introduction. Post-resuscitation care is regulated by international
guidelines. A milestone of these is the application of therapeutic
hypothermia (TH). The aims of our study were: to determine the 30-day-
mortality for our patients, to monitor the efficacy and effects of TH, and
to investigate serum protein S100B – as an early prognostic marker.
Materials and Methods. In our study, 57 patients, treated after
cardiopulmonary resuscitation (CPR) on a multidisciplinary intensive
care unit, were included. Patients were divided into groups who received
and who didn’t receive TH. 30-day-mortality was determined as an end-
point. Effects of TH were monitored using statistical analysis according
to clinical parameters and laboratory tests. Serum protein S100B levels
were measured with ELISA technique on 20 randomised patients at
admission and the 1st, 3rd and 5th day after CPR.
Results. Total 30-day-mortality was 74%. TH did not reduced the 30-day-
mortality (73% vs. 74%, p>0.05). We found a significant correlation
between TH and serum lactate concentration after admission (0h,
p=0.006) and at 12 (p=0.045) and 36 (p=0.049) hours after CPR. On the
3rd (p=0.005) and 4th (p=0.043) day after CPR, as a result of TH, platelet
count was significantly higher compared to normothermic samples.
There was no significant difference in protein S100B levels between the
normothermic and TH group and protein S100B levels did not correlate
with 30-day-mortality.
Conclusion. Despite recommendations of international guidelines, we
cannot prove the beneficial effect of TH, or a correlation of protein S100B
levels with a positive outcome.
Key words: cardiac arrest, cardiopulmonary resuscitation, post-
resuscitation care, therapeutic hypothermia, protein S100B
Introduction
Ischaemic heart disease is the leading cause of mortality worldwide. In
Europe cardiovascular disorders are responsible for 40% of total
mortality. In developed countries the major cause of out-of-hospital
sudden death is cardiac arrest with a survival rate of 5-35%. After
cardiopulmonary resuscitation (CPR) the rate of the return of
spontaneous circulation (ROSC) is 25-50%, but the chance that patients
survive without neurological deficit is less than 10%. (1) CPR is regulated
by international guidelines. It is well known that post-resuscitation
therapy basically determines the neurologic outcome. (2–4)
Hypothermia is the state, when body core temperature is below 36⁰C.
Hypothermia can be classified by its effects on the human body (mild 32-
34⁰C, moderate 28-32⁰C, deep <28⁰C). (5) Since the 1950s, moderate
hypothermia has been used in cardiac surgery to prevent cerebral
ischaemia. It was also applied after cardiac arrest (CA), but has been
stopped due to unclear benefits. (6) Therapeutic hypothermia (TH) after
ROSC has been recommended by the International Liaison Committee on
Resuscitation (ILCOR) since 2003 and by the European Resuscitation
Council (ERC) since 2005. Since 2010 ERC has recommended the use of
TH after CPR (32-34⁰C core temperature for 12-24 hours). TH could be
beneficial following primary cerebral injury by preventing further
neuronal damage. (5,7) After ROSC one of the major causes of mortality
is cerebral injury (68% of out-of-hospital, 23% of in-hospital cases). (4)
Former attempts to determine the level of cerebral injury and prognosis,
within the first 24 hours with clinical neurological or electro-
physiological methods were unreliable. Biochemical markers, such as
neuron specific enolase (NSE) and protein S100B (PS100B), may indicate
the level of cerebral injury and prognosis in an early phase. (8,9)
In our study the aims were to investigate the survival rate of patients
after CPR, ROSC, to determine the efficiency of TH in our practice, to




Our study was carried out in accordance with the ethical guidelines of the
2005 Declaration of Helsinki, and permission was obtained from the
Institutional Scientific and Human Research Ethics Committee of the
University of Pécs. Patients (n=57) treated on the multidisciplinary
intensive care unit (ICU) of University of Pécs between June 2009 and
February 2012 after CPR, ROSC were included in the study. In our
patient group the cause of CA and the initial cardiac electrical activity was
heterogeneous (table 1A) Patients with chronic disorders were not
excluded (table 1B). A written informed consent was acquired after
providing detailed information about the study design and blood
sampling to the closest relative of unconscious patients according to
national law. In the case of each patient, CPR, defibrillation, drug
administration were carried out under the advanced life support
recommendation of the Hungarian Resuscitation Committee which
complies with the ERC guideline. (10) Different types of initial cardiac
rhythm were not excluded. After ROSC ICU therapy was started at the
earliest time. To reach the recommended level of TH, 30ml/kg of cold
(4⁰C) 0.9% Saline infusion and additional external cooling (cooler blocks
over great blood vessels) were used. TH was maintained for 24 hours.
Core temperatures of the patients were measured at the upper
oesophagus. During ICU therapy regular laboratory blood tests
(including blood gas parameters, lactate levels, blood cell count,
electrolyte levels, C-reactive protein and organ function specific
parameters) were taken, blood samples were collected via an arterial
cannula, which were inserted at the time of ICU admission according to
local protocol. To compare the general condition of patients, the New
Simplified Acute Physiology Score (SAPSII) was measured in each case.
Patients were separated according to 30-day-mortality. To monitor
patient’s early neurological state, the Glasgow Coma Scale (GCS) was
used. Investigation of long-term neurological outcome and functional
capacity of the survivors was not the aim of the study.
Protein S100B assays
20 randomised patients were chosen to determine PS100B. Blood
samples were collected within 2 hours after CPR, intensive care unit
admission (1st sample) and after 24, 72 and 120 hours (2nd, 3rd, 4th
samples). Native blood samples were centrifuged (1500g, 10min) and
stored at –80⁰C until analysis. PS100B quantitative measurement was
performed by sandwich enzyme immunoassay according to
manufacturer’s instructions (RD192090100R, BioVendor –
Laboratornímedicína a.s., Brno, Czech Republic). The concentrations of
PS100B (ng/l) were determined spectrophotometrically at 450nm
absorption wavelength in comparison with the standard curve.
Statistical analysis
For statistical analysis SPSS v21 for Windows (IBM SPSS Statistics) was
used. Data were expressed as minimum, maximum and median. Non-
parametric data were analysed with Mann-Whitney U test. In
calculations, p<0.05 was considered significant.
Results
Patient mortality rate
Among the 57 patients (female: 19, male: 38), the overall mean age was
62 years, and there was no difference between the two genders (female:
64y, male: 61y). The duration of CPR was between 1 and 50 minutes
(mean: 14.5 minutes). After CPR, TH was applied on 22 patients. The
total 30-day-mortality was 74%. There was no difference in the 30-day-
mortality between the two genders and the age of the patients did not
influence the 30-day-mortality. In our study, TH did not reduce the 30-
day-mortality (73% vs. 74%). Neither the duration of CPR nor the initial
cardiac electrical activity (ventricular fibrillation, pulseless electrical
activity or asystole) influenced the mortality (73% vs 71% vs 78%). SAPSII
values were not altered between survivors and non-survivors. Glasgow
Coma Scale values on ICU admission were significantly related to 30-day-
mortality (p=0.047).To differentiate patients, a GCS cut-off-point of 6
was established. In the GCS<6 group the mortality was significantly
higher than in GCS≥6 group (table 2).
Effects of TH
In the TH group, serum lactate concentration after ICU admission (0h,
p=0.006) and at 12 (p=0.045) and 36 (p=0.049) hours after ROSC was
significantly higher compared to NT samples. The median serum lactate
concentration after TH was more than twice that in the normothermic
(NT) group, at the first measurement (6.3 mmol/l vs 2.8 mmol/l). In
both groups, lactate concentrations reached normal range after 12 hours
and stayed within this range in the further samples (figure 1). Medians of
serum bicarbonate (HCO3) in the TH group showed an increasing
tendency in the first 96 hours after ROSC. In NT patients, HCO3 levels
increased to normal serum range until the 12th hour, however, in the TH
group elevation was more sustained (normalisation at 36th hour). After
that, HCO3 concentrations rose to higher than normal range (from the
48th hour in NT group vs. 72th hour in TH group (figure 2).On the 3rd
(p=0.005) and 4th (p=0.043) days after ROSC, as a result of TH, platelet
count was significantly higher compared to NT samples. In the TH group,
median platelet count was higher in each measurement, although neither
in NT nor after TH, could higher-than-normal levels be measured (figure
3).
Protein S100B levels
Levels of serum PS100B measured in the 4th samples showed a
significant decrease compared to the 1St (p=0.001) and 2nd (p=0.019)
samples (figure 4). Among non-survivors, in the 1st and 2nd samples, a
tendency to higher serum levels was observed, which disappeared until
the 3rd and 4th samples, however the difference was not significant
between survivors and non-survivors (figure 5). There was no significant
difference in PS100B levels between the NT and TH group (figure 6), but




The incidence of out-of-hospital cardiac arrest (CA) is approximately
350,000 per year in Europe. (11) Corner stones of management are: early
recognition, early basic life support, early defibrillation (if necessary) and
early post-resuscitation therapy. After CA global anoxia occurs. The
extent of cellular injury is determined by the duration and rate of
hypoxia, individual cellular resistance and the extracellular environment.
(4)
Cerebral dysfunction which develops after CA can be completely
reversible within the first 5 minutes. After this period, ROS production
and hypoxia-generated calcium-ion movement causes excitatory
neurotransmitter (e.g. glutamate) release leading to further neuronal
injury. Most hypoxia-sensitive neurons are located in the basal ganglia,
hippocampus and cerebellum. (11) After CA, central nervous system
dysfunction may manifest at variable levels of cognitive dysfunction:
myoclonus, convulsions, coma and brain death. Cerebral injury may
occur via microcirculation- and autoregulation disturbances,
hyperpyrexia, hypoxia, hypercarbia or hyperglycaemia. (8)
According to the ERC guideline, published in 2010, TH improves
neurological outcome after CPR, consequently a reduction in total
mortality has been described in several publications. (12–16) In contrast,
in the present study TH did not alter 30-day-mortality. This might have
been influenced by the low number of patients and the efficiency of the
cooling method in our unit , although in a recent randomised study
Nielsen et al. (17) found that after out-of-hospital cardiac arrest of
presumed cardiac cause, hypothermia at a targeted temperature of 33°C
did not confer a benefit as compared with a targeted temperature of 36°C.
In paediatric practice, TH and consequent microcirculatory impairment
was associated with a higher mortality rate. (18) In contrast with Arrich
et al., (19) in the present study 30-day-mortality was not influenced by
the gender and age of the patients. The duration of CPR, and initial
cardiac activity did not significantly influence 30-day-mortality in our
study, but earlier findings reported elevated mortality rate after non-
shockable rhythms (20) and the duration of CPR as an independent
predictor of mortality. (21,22) It is well known that the original ILCOR
guideline recommended TH after ventricular fibrillation but for other
rhythms the „may also be beneficial” statement was used. (6) However,
over recent years, TH, after non-shockable rhythms, was found to
improve outcomes. (23) A GCS<6 consciousness on ICU admission was
related to significantly higher mortality rates compared to the GCS≥6
group. Hassan et al. (24) found the same relationship between GCS score
and mortality. In recent years „Full Outline of UnResponsiveness”
(FOUR) score has been widely used, which can eliminate the incorrect
assignment of verbal function in intubated patients (25,26) but positive
correlation between BIS values and GCS scores was also found, and BIS
values may predict the post-resuscitative outcome. (27)
Effects of TH
Today TH after ROSC is recommended by international guidelines. Since
2010 ERC recommends the use of TH after CPR (32-34⁰C core
temperature for 12-24 hours) as a beneficial method after primary
cerebral injury by preventing further neuronal damage. (5,7)
In the present study, serum lactate levels in the TH group were
significantly higher than in the NT group on ICU admission and in the
12th and 36th hours after ROSC. In contrast, Bernard et al. (11) measured
a significant difference just in the 18th and 24th hour after ROSC. This
alteration may be due to the duration of applied TH (12h vs 24h in our
practice). In parallel, we found a prolonged normalisation of serum
lactate levels in the TH group, which can be explained by decreased
lactate-clearance caused by TH. In the present study, lower
normalization tendency of serum bicarbonate concentrations was
measured in the TH group compared to the NT group, which was
associated with a longer elevation to normal values. This may be
influenced by a decreased dissociation rate of carbonic acid at lower
temperatures. (4,28) Contrary to an earlier publication (29) – where cold
intravenous fluid volume was applied to reach TH, as a result a lower
platelet count was measured – we found higher thrombocyte counts in
the TH group. In an attempt to find an explanation, no completely
acceptable reasons were found, further investigation is required.
Protein S100B levels
PS100B is a small acidic protein, a member of the calcium-binding
protein family. PS100B is synthesized by astrocytes, oligodendrocytes
and Schwann-cells. This protein is the biochemical marker of the
integrity of the blood-brain-barrier (BBB). After BBB dysfunction, the
PS100B level increases in the cerebrospinal fluid and serum. High
PS100B levels correlate with poor survival. (30) Compared to NSE (a
dimer enzyme (2-phosph-D-glycerate-dehydrogenase), synthesized by
neuroectodermal-origin-cells, also a serum marker of cerebral injury),
PS100B was found to be more reliable as an early predictor of poor
neurological outcome after CA. (31,32)
We measured decreasing levels of PS100B, from the 1st to 4th samples,
that can comply with the relative short half-life (120min) of this protein
in the serum. (30) Several human investigations have found that PS100B
is a good early predictor of mortality after ROSC (31–34) however,
complete agreement cannot be found. In the present investigation there
was no significant alteration in PS100B between the survivor and non-
survivors groups, based on 30-day-mortality. Our result can be compared
to the findings of Song et al. (35) Among 151 patients who experienced
out-of -hospital resuscitation, they found that higher levels of PS100B at
the start of CPR were significantly associated with lower survival on
admission, but the PS100B levels were not different for 1-month survival
rates between survivors and non-survivors. We could not measure
differences in PS100B levels in the TH and NT groups which might be
influenced by the low number of cases, and the same mortality observed
in the groups.
Conclusions
Despite recommendations of international guidelines, efficacy of TH in
the ICU after CPR has become questionable in recent years. Results of
different trials may be conflicting. Such a tendency can be recognised in
connection with the clinical use of PS100B, as an early predictor of
mortality and neurological outcome after CA, ROSC. Despite a lack of
evidence, the dominance of findings in support seems to be strong. In our
study we could not prove the beneficial effect of TH, or a relationship
between PS100B levels and positive outcome, although the low case
number was a limitation of the present investigation.
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Figure 1. Serum lactate concentrations of normothermic (NT-grey
boxes) and therapeutic hypothermia (TH-striped boxes) groups. Data are
expressed as median and inter-quartile range (IQR; standard 25th-75th
percentile and 5th and 95th confidence interval). *p<0.05 NT vs. TH
Figure 2. Serum bicarbonate concentrations of normothermic (NT-grey
boxes) and therapeutic hypothermia (TH-striped boxes) groups. Data are
expressed as median and inter-quartile range (IQR; standard 25th-75th
percentile and 5th and 95th confidence interval).
Figure 3. Thrombocyte count of normothermic (NT-grey boxes) and
therapeutic hypothermia (TH-striped boxes) groups. Data are expressed
as median and inter-quartile range (IQR; standard 25th-75th percentile
and 5th and 95th confidence interval). *p<0.05
Figure 4. Serum protein S100B levels in study patients. Data are
expressed as median and inter-quartile range (IQR; standard 25th-75th
percentile and 5th and 95th confidence interval). *p<0.05, ns: non-
significant
Figure 5. Serum protein S100B levels among non-survivors (NS – grey
boxes) and survivors (S – striped boxes) Data are expressed as median
and inter-quartile range (IQR; standard 25th-75th percentile and 5th and
95th confidence interval). *p<0.05, ns: non-significant
Figure 6. Serum protein S100B levels in normothermic (NT – grey
boxes) and therapeutic hypothermia (TH – striped boxes) groups. Data
are expressed as median and inter-quartile range (IQR; standard 25th-
75th percentile and 5th and 95th confidence interval). *p<0.05, ns: non-
significant
Figure 7. Serum protein S100B levels in normothermic (NT – grey
boxes) and therapeutic hypothermia (TH – striped boxes) groups among
survivors. Data are expressed as median and inter-quartile range (IQR;
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